CareDx, Inc
CDNA
Rank in Stocks
#4470
CareDx, Inc. is a global innovator specializing in the discovery, development,... CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
Share Price
$66.87
Market Cap
$3.46B
Change (1 day)
4.48%
Change (1 year)
364.02%
Country
US
Trade CareDx, Inc (CDNA)
Category
Healthcare
P/E ratio for CareDx, Inc (CDNA)
P/E ratio as of October 2026 TTM: 30.06
According to CareDx, Inc latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 30.06. At the end of 2023 the company had a P/E ratio of -3.39.
P/E ratio history for CareDx, Inc from 2012 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 30.06 | 39.82% |
| 2024 | 21.50 | -734.14% |
| 2023 | -3.39 | -57.30% |
| 2022 | -7.94 | -89.75% |
| 2021 | -77.49 | -56.94% |
| 2020 | -179.95 | 334.79% |
| 2019 | -41.39 | 115.98% |
| 2018 | -19.16 | 521.35% |
| 2017 | -3.08 | 173.28% |
| 2016 | -1.13 | -79.55% |
| 2015 | -5.52 | -110.22% |
| 2014 | 53.99 | -386.60% |
| 2013 | -18.84 | 42.83% |
| 2012 | -13.19 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 36.15 | 20.27% |
US
|
|
| 39.77 | 32.31% |
US
|
|
| -290.26 | -1,065.54% |
US
|
|
| - | - |
CN
|
|
| 34.18 | 13.71% |
US
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.